HSE begins talks on CF drug Orkambi
News relief to patients with cystic fibrosis and families
Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.
The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.
The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, ...
